Home Featured Page 204

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

U.S. FDA Approves Nova Mentis Orphan Drug Application

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

1...203204205...296 Page 204 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

U.S. FDA Approves Nova Mentis Orphan Drug Application

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY